lms method

Alpha-1 Antitrypsin Deficiency: Why fragmented care costs lives

Alpha-1 antitrypsin deficiency presents as both a respiratory and hepatic disease, often leading to diagnostic delays and suboptimal management due to fragmented care.

Air pollution: Why policies fail, and patients pay the price

Despite clear evidence linking air pollution to adverse health outcomes, effective implementation of protective policies remains a significant hurdle.

Respiratory care: Why neurology's long-acting therapies could be key

Insights from multiple sclerosis treatment paradigms offer a framework for developing ultra-long-acting therapies in respiratory care, addressing adherence and disease progression.

Rethink PDE inhibition in COPD: Not all isoforms are equal

Phosphodiesterase (PDE) inhibitors offer therapeutic potential in COPD, but adverse effects, particularly nausea with PDE4 inhibitors and cardiovascular risks with chronic PDE3 inhibition, limit their broader application.

RSV and COVID-19 vaccines: Why are we still underestimating their impact?

Vaccination against RSV and COVID-19 offers a critical strategy for mitigating the burden of respiratory diseases, particularly in vulnerable populations.

Severe asthma: Why targeted therapies miss some Type 2 patients

Emerging clinical insights suggest the distal airways play a more central role in Type 2 severe asthma pathophysiology than previously understood.

PH-ILD: Why current vasodilators fall short, and what's next

An inhaled sGC activator is under investigation for pulmonary hypertension associated with interstitial lung disease, a condition with significant unmet need.

Beyond rescue inhalers: What really keeps COPD patients out of hospital?

Preventing hospital admissions for COPD requires a comprehensive approach, moving beyond acute symptom management to address the underlying disease progression and comorbidities.

COPD exercise limits: Is your oxygen therapy doing enough?

High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.